Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 248 of 5804
-
Brain pacemaker could tame tough OCD
Disease control Recruiting nowThe goal of this clinical trial is to learn if deep brain stimulation (DBS) works to treat refractory obsessive-compulsive disorder (OCD). The main questions it aims to answer are: * Assess the effects of the anteromedial sub-thalamic nucleus (amSTN)stimulation on obsessive/comp…
Phase: NA • Sponsor: Nader Pouratian • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Could an allergy pill protect cancer patients from nerve pain?
Prevention Recruiting nowThis is a double-blinded randomized controlled clinical trial that aims to study if desloratadine can reduce rates of peripheral neuropathy development in patients with breast cancer receiving taxane chemotherapy. Researchers will compare desloratadine to a placebo (look-alike su…
Phase: PHASE2 • Sponsor: Montefiore Medical Center • Aim: Prevention
Last updated Jun 27, 2026 13:00 UTC
-
Vulvar cancer study aims to spare women from unnecessary surgery
Disease control Not yet recruitingThis study is a phase III, open label, multicentre, three-group, randomised clinical trial. The primary aim of this study is to determine whether intensive groin ultrasound monitoring (1) is effective and safe to replace invasive groin lymph node dissection (LND) to manage vulvar…
Phase: PHASE3 • Sponsor: Queensland Centre for Gynaecological Cancer • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Virus cocktail takes on tough liver tumors
Disease control Not yet recruitingThis prospective study aims to investigate the efficacy and safety of peritumoral injection of the oncolytic virus H101 in combination with stereotactic body radiotherapy (SBRT), PD-1 monoclonal antibody, chemotherapy, and targeted therapy for the treatment of patients with unres…
Phase: PHASE2 • Sponsor: Jun Huang • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Bladder cancer showdown: can radiation and chemotherapy match surgery?
Disease control Not yet recruitingYour text is mostly clear and well-structured. Here's a slightly polished version for improved clarity and flow: This is a randomized, non-inferiority study comparing radiochemotherapy to radical cystectomy in patients with muscle-invasive bladder cancer. The primary outcome is …
Phase: NA • Sponsor: Brazilian Clinical Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Old drug, new hope: colchicine may stop Post-Clot leg damage
Disease control Not yet recruitingDeep vein thrombosis (DVT) is a condition in which a blood clot forms in the deep veins of the leg and can lead to long-term problems such as leg pain, swelling, and reduced quality of life. Standard treatment with blood-thinning medication lowers the risk of complications, but s…
Phase: PHASE3 • Sponsor: Azienda Sanitaria Locale ASL 6, Livorno • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo therapy aims to control breast cancer brain metastases
Disease control Not yet recruitingThis is a prospective, open-label, exploratory clinical trial designed to evaluate the efficacy and safety of brain radiotherapy combined with dalpiciclib and endocrine therapy in HR-positive/HER2-negative advanced breast cancer patients with brain metastases. A total of 46 patie…
Phase: PHASE2 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New drug shows promise in destroying amyloidosis cells
Disease control Not yet recruitingThis research study is for people who have newly diagnosed with AL (light chain) amyloidosis and have not yet received any treatment for this condition. The purpose of this study is to evaluate whether elranatamab, a type of immunotherapy drug, can produce deep remissions and org…
Phase: PHASE2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug cocktail aims to boost transplant success in elderly leukemia patients
Disease control Not yet recruitingAcute myeloid leukemia (AML) is a serious blood cancer that mainly affects older adults. For patients who achieve their first complete remission (CR1), allogeneic hematopoietic stem cell transplantation (HSCT) may provide a chance for long-term survival. However, relapse after tr…
Phase: NA • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Sputum DNA test aims to outsmart Drug-Resistant TB
Diagnosis Not yet recruitingResistance to anti-tuberculosis drugs is a continually growing problem. Multidrug-resistant tuberculosis (MDRTB) is resistance to at least rifampicin and isoniazid, and extensively drug-resistant TB is additional resistance to a fluoroquinolone and a second injectable line drug. …
Phase: NA • Sponsor: University of Cape Town • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
New study aims to shield aging brains from Surgery's mental fog
Prevention Not yet recruitingNeurocognitive complications, mainly delirium and neurocognitive disorders, are common cerebral complications in older patients after surgery and associated with worse long-term outcomes. An ongoing 2×2 factorial trial conducted by the investigators plan to test the effects of pe…
Phase: PHASE4 • Sponsor: Peking University First Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:32 UTC
-
New hope for rare kidney disease: experimental drug YOLT-203 enters phase 2 trial
Disease control Not yet recruitingThis study will be conducted to evaluate the efficacy and safety of YOLT-203 in children and adults with Primary Hyperoxaluria Type 1. After the initial randomized, 6-month double-blind, placebo-controlled period, participants who were initially assigned to placebo will receive …
Phase: PHASE2 • Sponsor: YolTech Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New scan could spot hidden prostate cancer spread
Diagnosis Not yet recruitingThe investigators are imaging patients with newly diagnosed prostate cancer using a new Positron Emission Tomography (PET) imaging agent (68Ga-NYM032) in order to evaluate the safety and diagnostic performance.
Phase: PHASE3 • Sponsor: Norroy Bioscience Co., LTD • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
Promising drug cocktail aims to shrink aggressive nasal tumors before surgery
Disease control Not yet recruitingT4 stage sinonasal adenoid cystic carcinoma (SNACC) is a rare but aggressive cancer in the nasal cavity and sinuses. These tumors often invade the skull base, eye socket, or brain covering (dura), making complete surgical removal difficult and carrying a high risk of recurrence e…
Phase: PHASE2 • Sponsor: Eye & ENT Hospital of Fudan University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for aggressive lymphoma: triple-drug combo enters human trials
Disease control Not yet recruitingSingle-Arm Clinical Study of Zeprumetostat in Combination with Glofitamab + GemOx in Patients with Relapsed/ Refractory DLBCL
Phase: PHASE1, PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Engineered immune cells take aim at stubborn cancers
Disease control Recruiting nowPatients with refractory and/or recurrent solid tumor have poor prognosis despite complex multimodel therapy and therefore, novel approaches are urgently needed. This study attempts to treat these diseases using T cells genetically modified with a 4th generation lentiviral chimer…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New plug could boost aortic repair success
Disease control Recruiting nowThe goal of this prospective, multicenter, randomized controlled clinical trial is to evaluate the safety and efficacy of the WeFlow-EndoSeal™ vAorta Vascular Plug System combined with thoracic endovascular aortic repair (TEVAR) in patients diagnosed with Stanford type B aortic d…
Phase: NA • Sponsor: Hangzhou Endonom Medtech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug candidate SHR-3079 targets Hard-to-Treat lymphoma
Disease control Not yet recruitingThe study is being conducted to evaluate the safety and tolerability of SHR-3079, and to explore the Dose-limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D). This study also preliminarily evaluated the efficacy of SHR-3079 in patients wi…
Phase: PHASE1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Glowing light could spot oral cancer before it starts
Prevention ENROLLING_BY_INVITATIONPatients attending the Department of Oral Mucosal and Periodontal Diseases at the University Dental Center of the Medical University of Warsaw who provide written informed consent will be invited to participate in the study. Participation will begin with completing a short, anon…
Phase: NA • Sponsor: Medical University of Warsaw • Aim: Prevention
Last updated Jul 08, 2026 00:00 UTC
-
AI-Powered skin patch could bring TB prevention to People's doorsteps
Prevention Not yet recruitingThe SCAF-TB study aims to evaluate how the WHO-endorsed SIILTIBCY skin test can be best implemented to test close contacts for tuberculosis infection (TBI) in Tajikistan and Tanzania, either facility-based or home-based delivered by community health workers (CHWs) with or without…
Phase: NA • Sponsor: KNCV Tuberculosis Foundation • Aim: Prevention
Last updated Jul 22, 2026 00:00 UTC